By InvitationNot Applicable

Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant

United States10 participantsStarted 2025-08-29

Plain-language summary

The primary objective of this Phase 1/2 long-term follow-up (LTFU) study is to assess the long-term safety and tolerability of LX2020 for the treatment of arrhythmogenic cardiomyopathy (ACM) due to a plakophilin-2 gene (PKP2) pathogenic variant (PKP2-ACM).

Who can participate

Age range18 Years – 67 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants who received LX2020 in study LX2020-01 Exclusion Criteria: * Concurrent enrollment in any other clinical investigation involving use of an investigational agent.

What they're measuring

Percentage of subjects who experienced at least 1 treatment emergent adverse event (TEAE) and/or 1 treatment emergent serious adverse event (TESAE).

Timeframe: 4 years

Trial details

NCT IDNCT07050160

SponsorLexeo Therapeutics

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2030-08

View on ClinicalTrials.gov More Arrhythmogenic Cardiomyopathy trials